AstraZeneca (AZN) Shares Drop 9% Following Heart Drug Trial Failure
AstraZeneca's shares dropped nearly 9% following the failure of its late-stage clinical trial for the heart drug Wainua, which did not achieve its primary goal of reducing deaths and heart-related emergencies.